Five-year outcomes of sirolimus-eluting versus paclitaxel-eluting stents: A propensity matched study: Clinical evidence of late catch-up?

Young Guk Ko, Jung Sun Kim, Donghoon Choi, Myeongki Hong, Pil Ki Min, Young Won Yoon, Bum Kee Hong, Byoung Kwon Lee, Hyuck Moon Kwon, Byeong Keuk Kim, Sung Jin Oh, Dong Wun Jeon, Joo Young Yang, Yangsoo Jang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Siroliums-eluting stents (SES) and paclitaxel-eluting stents (PES) have been widely used for the treatment of coronary artery disease. We investigated 5-year clinical outcomes of patients treated with SES versus PES in a multicenter registry. Methods: We used a propensity score matching method with 2:1 matching, including 512 patients treated with SES and 256 patients treated with PES from March 2003 to December 2004. The primary endpoint was major adverse cardiac events, which included all-cause death, myocardial infarction (MI), and target vessel revascularization (TVR). Results: After matching, baseline characteristics were similar between the two groups. At 5 years, cumulative survival free of major adverse cardiac events, MI, and stent thrombosis did not differ between the two groups. Survival free of TVR at 5 years was higher in the SES group (88.4%) than the PES group (84.3%, Log-rank p = 0.016). In contrast to the trend toward more likely target lesion revascularization in the PES group during the first 2 years (hazard ratio 0.62, p = 0.057), target lesion revascularization tended to occur more frequently in the SES group from 2 to 5 years (hazard ratio 2.26, p = 0.099). Conclusions: Long-term risk of TVR was slightly lower with SES, compared with PES, despite no significant difference in major adverse cardiac events. However, the SES group had more frequent target lesion reintervention 2 to 5 years after stent implantation, whereas reintervention in the PES group occurred mainly within the first 2 years. This may reflect the temporal difference in neointimal growth of the two stent types.

Original languageEnglish
Pages (from-to)302-306
Number of pages5
JournalInternational Journal of Cardiology
Volume152
Issue number3
DOIs
Publication statusPublished - 2011 Nov 3

Fingerprint

Sirolimus
Paclitaxel
Stents
Clinical Studies
Myocardial Infarction
Propensity Score
Survival

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Ko, Young Guk ; Kim, Jung Sun ; Choi, Donghoon ; Hong, Myeongki ; Min, Pil Ki ; Yoon, Young Won ; Hong, Bum Kee ; Lee, Byoung Kwon ; Kwon, Hyuck Moon ; Kim, Byeong Keuk ; Oh, Sung Jin ; Jeon, Dong Wun ; Yang, Joo Young ; Jang, Yangsoo. / Five-year outcomes of sirolimus-eluting versus paclitaxel-eluting stents : A propensity matched study: Clinical evidence of late catch-up?. In: International Journal of Cardiology. 2011 ; Vol. 152, No. 3. pp. 302-306.
@article{b5d5ca80006e4f428cbf8b7e7f25780e,
title = "Five-year outcomes of sirolimus-eluting versus paclitaxel-eluting stents: A propensity matched study: Clinical evidence of late catch-up?",
abstract = "Background: Siroliums-eluting stents (SES) and paclitaxel-eluting stents (PES) have been widely used for the treatment of coronary artery disease. We investigated 5-year clinical outcomes of patients treated with SES versus PES in a multicenter registry. Methods: We used a propensity score matching method with 2:1 matching, including 512 patients treated with SES and 256 patients treated with PES from March 2003 to December 2004. The primary endpoint was major adverse cardiac events, which included all-cause death, myocardial infarction (MI), and target vessel revascularization (TVR). Results: After matching, baseline characteristics were similar between the two groups. At 5 years, cumulative survival free of major adverse cardiac events, MI, and stent thrombosis did not differ between the two groups. Survival free of TVR at 5 years was higher in the SES group (88.4{\%}) than the PES group (84.3{\%}, Log-rank p = 0.016). In contrast to the trend toward more likely target lesion revascularization in the PES group during the first 2 years (hazard ratio 0.62, p = 0.057), target lesion revascularization tended to occur more frequently in the SES group from 2 to 5 years (hazard ratio 2.26, p = 0.099). Conclusions: Long-term risk of TVR was slightly lower with SES, compared with PES, despite no significant difference in major adverse cardiac events. However, the SES group had more frequent target lesion reintervention 2 to 5 years after stent implantation, whereas reintervention in the PES group occurred mainly within the first 2 years. This may reflect the temporal difference in neointimal growth of the two stent types.",
author = "Ko, {Young Guk} and Kim, {Jung Sun} and Donghoon Choi and Myeongki Hong and Min, {Pil Ki} and Yoon, {Young Won} and Hong, {Bum Kee} and Lee, {Byoung Kwon} and Kwon, {Hyuck Moon} and Kim, {Byeong Keuk} and Oh, {Sung Jin} and Jeon, {Dong Wun} and Yang, {Joo Young} and Yangsoo Jang",
year = "2011",
month = "11",
day = "3",
doi = "10.1016/j.ijcard.2010.07.023",
language = "English",
volume = "152",
pages = "302--306",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Five-year outcomes of sirolimus-eluting versus paclitaxel-eluting stents : A propensity matched study: Clinical evidence of late catch-up? / Ko, Young Guk; Kim, Jung Sun; Choi, Donghoon; Hong, Myeongki; Min, Pil Ki; Yoon, Young Won; Hong, Bum Kee; Lee, Byoung Kwon; Kwon, Hyuck Moon; Kim, Byeong Keuk; Oh, Sung Jin; Jeon, Dong Wun; Yang, Joo Young; Jang, Yangsoo.

In: International Journal of Cardiology, Vol. 152, No. 3, 03.11.2011, p. 302-306.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Five-year outcomes of sirolimus-eluting versus paclitaxel-eluting stents

T2 - A propensity matched study: Clinical evidence of late catch-up?

AU - Ko, Young Guk

AU - Kim, Jung Sun

AU - Choi, Donghoon

AU - Hong, Myeongki

AU - Min, Pil Ki

AU - Yoon, Young Won

AU - Hong, Bum Kee

AU - Lee, Byoung Kwon

AU - Kwon, Hyuck Moon

AU - Kim, Byeong Keuk

AU - Oh, Sung Jin

AU - Jeon, Dong Wun

AU - Yang, Joo Young

AU - Jang, Yangsoo

PY - 2011/11/3

Y1 - 2011/11/3

N2 - Background: Siroliums-eluting stents (SES) and paclitaxel-eluting stents (PES) have been widely used for the treatment of coronary artery disease. We investigated 5-year clinical outcomes of patients treated with SES versus PES in a multicenter registry. Methods: We used a propensity score matching method with 2:1 matching, including 512 patients treated with SES and 256 patients treated with PES from March 2003 to December 2004. The primary endpoint was major adverse cardiac events, which included all-cause death, myocardial infarction (MI), and target vessel revascularization (TVR). Results: After matching, baseline characteristics were similar between the two groups. At 5 years, cumulative survival free of major adverse cardiac events, MI, and stent thrombosis did not differ between the two groups. Survival free of TVR at 5 years was higher in the SES group (88.4%) than the PES group (84.3%, Log-rank p = 0.016). In contrast to the trend toward more likely target lesion revascularization in the PES group during the first 2 years (hazard ratio 0.62, p = 0.057), target lesion revascularization tended to occur more frequently in the SES group from 2 to 5 years (hazard ratio 2.26, p = 0.099). Conclusions: Long-term risk of TVR was slightly lower with SES, compared with PES, despite no significant difference in major adverse cardiac events. However, the SES group had more frequent target lesion reintervention 2 to 5 years after stent implantation, whereas reintervention in the PES group occurred mainly within the first 2 years. This may reflect the temporal difference in neointimal growth of the two stent types.

AB - Background: Siroliums-eluting stents (SES) and paclitaxel-eluting stents (PES) have been widely used for the treatment of coronary artery disease. We investigated 5-year clinical outcomes of patients treated with SES versus PES in a multicenter registry. Methods: We used a propensity score matching method with 2:1 matching, including 512 patients treated with SES and 256 patients treated with PES from March 2003 to December 2004. The primary endpoint was major adverse cardiac events, which included all-cause death, myocardial infarction (MI), and target vessel revascularization (TVR). Results: After matching, baseline characteristics were similar between the two groups. At 5 years, cumulative survival free of major adverse cardiac events, MI, and stent thrombosis did not differ between the two groups. Survival free of TVR at 5 years was higher in the SES group (88.4%) than the PES group (84.3%, Log-rank p = 0.016). In contrast to the trend toward more likely target lesion revascularization in the PES group during the first 2 years (hazard ratio 0.62, p = 0.057), target lesion revascularization tended to occur more frequently in the SES group from 2 to 5 years (hazard ratio 2.26, p = 0.099). Conclusions: Long-term risk of TVR was slightly lower with SES, compared with PES, despite no significant difference in major adverse cardiac events. However, the SES group had more frequent target lesion reintervention 2 to 5 years after stent implantation, whereas reintervention in the PES group occurred mainly within the first 2 years. This may reflect the temporal difference in neointimal growth of the two stent types.

UR - http://www.scopus.com/inward/record.url?scp=80055048980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055048980&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2010.07.023

DO - 10.1016/j.ijcard.2010.07.023

M3 - Article

C2 - 20708806

AN - SCOPUS:80055048980

VL - 152

SP - 302

EP - 306

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -